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Background: Lung cancer initially manifesting as gastrointestinal
(GI)-tract metastasis is exceedingly rare, representing a diagnostic
challenge and a late-stage disease sign. The clinicopathologic char-
acteristics of the largest series of lung carcinomas initially present-
ing with GI involvement were described, focusing on differential
diagnosis and therapeutic options.
Methods: Eighteen consecutive cases of lung cancer (11 surgical
specimens and 7 biopsies) initially diagnosed on GI histologic samples
were identified during routine pathologist practice. All cases were
immunostained with thyroid transcription factor-1 (TTF-1), caudal-
related homeobox 2 (CDX2), and cytokeratins 7 (CK7) and 20
(CK20). Clinical and radiological data were obtained in all cases.
Results: There were 10 women and 8 men with a mean age of 68.5
years. The small bowel was the most common GI involved site (12
cases), followed by the stomach (four) and large intestine (two).
Only half of cases were correctly diagnosed on GI biopsies. Four-
teen patients died shortly from disease (mean follow-up, 3 months);
two are still alive with multiple metastases, and two patients with the
GI tract as the unique site of metastasis underwent pulmonary
lobectomy and chemotherapy and are alive without evidence of
disease. At morphology, there were 10 large cell undifferentiated
carcinomas and eight adenocarcinomas. All cases were immuno-
stained for CK7 and 89% for TTF-1, whereas CK20 and CDX2 were
completely negative.
Conclusion: Lung cancer presenting as GI-tract metastasis is prob-
ably more frequent than expected, and pathologists should always
keep in mind this possibility when dealing with undifferentiated GI
carcinoma. Immunostaining with TTF-1, CDX2, CK7, and CK20 is
helpful in highlighting lung primary. Although GI metastasis from
lung cancer is associated with dismal outcomes, pulmonary resec-
tion coupled with chemotherapy might represent a therapeutic op-
tion in selected patients with a solitary GI-tract metastasis.
Key Words: Lung cancer, Metastasis, Gastrointestinal tract, Immu-
nohistochemistry, TTF-1.
(J Thorac Oncol. 2007;2: 115–120)
The occurrence of metastasis to the gastrointestinal (GI)tract from lung cancer is a rarely mentioned but well-
recognized phenomenon in the literature, the small bowel
representing the most common site of metastatic involve-
ment.1–9 The actual incidence of GI-tract metastasis from
lung cancer is variable (0.5%–10%) and mainly depends on
the evaluation method (endoscopy, surgical specimens, au-
topsies) of the study.1–9 In addition, GI-tract involvement by
lung cancer is considered a late stage of disease because of
diffuse hematogenous tumor spread and is generally detected
in patients with a documented previous history of a primary
lung malignancy.1–14 By contrast, the finding of a lung cancer
initially manifesting as GI-tract involvement is exceedingly
rare and is usually mentioned in literature in isolated case
reports.15–20
The aims of our study were to describe the clinicopath-
ologic features of the largest series of primary lung cancers
manifesting at initial diagnosis as GI metastases; discussing
the differential diagnosis, with special interest on the role of
a limited panel of immunostains, including cytokeratins 7
(CK7) and 20 (CK20), thyroid transcription factor-1 (TTF-1),
and caudal-related homeobox 2 (CDX2); and the alternative
therapeutic options in this uncommon oncologic setting.
MATERIALS AND METHODS
Eighteen consecutive cases of lung tumors originally
diagnosed on biopsies or surgical resection of the GI tract
were collected during routine histological examinations at the
Section of Pathologic Anatomy of the Hospital Policlinico
between 1999 and 2006. In the same period of time, 3432
new cases of lung cancer were diagnosed. All cases were also
reviewed by two pathologists (GR and AC) and were classi-
fied according to the recent 2004 World Health Organization
classification of lung tumors.21 The criteria for diagnosis
included morphologic and immunohistochemical features
consistent with a primary pulmonary tumor as well as the
clinicoradiologic demonstration of a primary lung tumor and
exclusion of tumors elsewhere.
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All available hematoxylin- and eosin-stained slides
were reviewed. Specimens consisted of 11 surgical resections
(nine small bowel surgical resections, one gastrectomy, one
hemicolectomy), and seven GI biopsies (three from the stom-
ach, two from the duodenum, one from the right colon, and
one from the stomach and duodenum). Immunohistochemical
studies were performed on 3-m-thick sections obtained
from a representative paraffin-embedded block using an au-
tomated immunostainer (Benchmark, Ventana, Tucson, AZ).
The primary antibodies used included the following: TTF-1
(clone 8G7G3, Dakopatts, Glostrup, Denmark; 1:100 dilu-
tion), CDX2 ((clone 7C7/D4, Biogenex, San Ramon, CA;
1:200 dilution), CK7 (clone OV-TL 12/30, Dako; 1:50 dilu-
tion), and CK20 (clone KS20.8, Dako; 1:50 dilution).
Clinical and follow-up information were obtained in all
cases from the patients’ records and the referring physicians.
RESULTS
Clinical Features
The most important clinical characteristics of the pa-
tients are summarized in Table 1. Briefly, the ages of the
patients ranged from 44 to 92 years (mean, 68.5 years). There
were 10 women and 8 men, 14 of whom had a smoking
history. All patients presented GI symptoms at the time of
initial diagnosis. In 12 cases, the patients had involvement of
the small intestine leading to small bowel surgical resection
for intestinal obstruction and/or perforation in nine cases. In
all cases but one, there was a solitary metastatic site in the GI
tract, whereas one case had synchronous involvement of the
stomach and small intestine (case 16). The stomach was the
main site of symptoms in five cases, and two patients pre-
sented with large intestine involvement. Fourteen patients
died of disease at a mean follow-up of 3 months (range, 1–14
months) from the initial diagnosis. The remaining four pa-
tients are alive with disease, with a very short follow-up
ranging from 2 weeks to 5 months. In three cases, the
radiologic work-up (total-body computed tomography scan
and positron emission tomography [PET] scan) confirmed
that the GI tract was the only metastatic site of disease; then,
the patients underwent subsequent pulmonary resection of the
primary tumor, followed by cisplatin- and gemcitabine-based
chemotherapy. The interval from original diagnosis to lung
discovery ranged from 1 week to 3 months; in one case, the
diagnosis was performed at autopsy. In half of cases, a
metastatic lung tumor was promptly suspected on the biopsy
from the GI tract. In all patients, a lung nodule/mass was
radiologically documented; only in one third of cases were
we able to match both metastatic and primary tumors at
histology (three pulmonary lobectomies; two bronchial biop-
sies and one transthoracic biopsy).
Pathologic Features
The most important pathologic and immunohistochem-
ical features are summarized in Table 2.
At morphology, 10 tumors were characterized by a
similar morphology consisting of an undifferentiated prolif-
eration of large, epithelioid, poorly cohesive tumor cells
arranged singly or in sheets and intermingled with and dis-
secting the normal glandular structures of the GI mucosa
(Figure 1A, B). These elements showed a large amount of
eosinophilic cytoplasm, well-defined cell borders, and a
round nucleus with prominent nucleulus. Occasionally, the
tumor cells showed the presence of small, intracytoplasmic
mucin deposits that were periodic acid–Schiff positive. Three
of these cases also showed a giant cell carcinoma component





(months) Symptomatology Site of First Diagnosis and Therapy Follow-up
1 76/F Yes Intestinal perforation Small bowel resection DOD (1)
2 73/F Yes Rectal bleeding Hemicolectomy DOD (4)
3 73/M Yes Incidental (polyp of the cecum) colon biopsy DOD (2)
4 47/M Yes Intestinal obstruction Small bowel resection  PL  CT ANED (5)
5 60/F Yes Intestinal obstruction Small bowel resection  PL  CT ANED (3)
6 44/F Yes Abdominal pain/pyrosis Small bowel resection DOD (1)
7 62/M Yes Intestinal obstruction Small bowel resection DOD (3)
8 92/M No Jaundice, weight loss  anemia Duodenum biopsy DOD (1)
9 80/M Yes Anemia, gastric bleeding Duodenum biopsy DOD (1)
10 68/F No Intestinal obstruction Small bowel resection  CT DOD (4)
11 72/F Yes Intestinal obstruction Small bowel resection DOD (4)
12 68/F No Intestinal obstruction Small bowel resection DOD (2)
13 81/F Yes Anemia, epigastric pain Gastric biopsy DOD (1)
14 75/M Yes Anemia, gastric bleeding Total gastrectomy  PL  CT DOD (14)
15 65/F No Anemia, melena Gastric biopsy DOD (2)
16 64/F Yes Weight loss, pyrosis Gastric and duodenum biopsies  CT AWD (2)
17 79/M Yes Intestinal obstruction Small bowel resection DOD (3)
18 54/M Yes Weight loss, epigastric pain Gastric biopsy  CT AWD (2 weeks)
F, female; M, male; PL, pulmonary lobectomy; CT, chemotherapy; ANED, alive without evidence of disease; AWD, alive with disease; DOD, died of disease.
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with a neoplastic growth of discohesive, very large, undiffer-
entiated, and sometimes multinucleated giant cells with ple-
omorphic nuclei, abundant cytoplasm, and phenomenon of
emperipolesis (Figure 1C). One case presented a rhabdoid
cell component consisting of large cells with abundant eosin-
ophilic cytoplasm, eccentric nucleus, and intracytoplasmic
eosinophilic globules (Figure 1D). Eight tumors appeared as
poorly differentiated adenocarcinomas, three of which ap-
peared as solid adenocarcinomas with mucin production.
In all resected cases, the finding at low magnification of
a neoplastic growth diffusely involving the serosal surface,
the perivisceral adipose tissue, and the intestinal wall with or







GI and Lung Diagnosis TTF-1 CK7 CK20 CDX2
1 ADC G3 ADC nos No At autopsy    
2 LCC* LCC nos No 3 months    
3 ADC G3 ADC nos No 1 month    
4 ADC G3† Lung met Yes —    
5 ADC G3 Lung met Yes —    
6 LCC# LCC nos No 1 week    
7 LCC Lung met Yes —    
8 LCC Lung met No —    
9 LCC Lung met No —    
10 ADC G3 ADC nos No 2 months    
11 LCC LCC nos Yes 1 month    
12 LCC# LCC nos No 1 month    
13 LCC Lung met No —    
14 ADC G3† Lung met† Yes —    
15 LCC LCC nos No 1 month    
16 ADC G3† Lung met† No —    
17 LCC# LCC nos No 2 months    
18 ADC G3 Lung met Yes —    
ADC, adenocarcinoma; G3, histologic grade 3 or poorly differentiated; LCC, large cell carcinoma; nos, not otherwise specified about the primary; lung met, metastatic tumor
from lung primary; GI, gastrointestinal; TTF-1, thyroid transcription factor-1; CK7, cytokeratin 7; CK20, cytokeratin 20; † solid with mucus production variant; # giant cell carcinoma
component; * rhabdoid cell component.
FIGURE 1. Duodenum biopsy (A,
case 16; hematoxylin–eosin stain-
ing, 125; black arrows) and a
small bowel resection (B, case 7;
hematoxylin–eosin staining, 125)
showing large, undifferentiated tu-
mor cells with infiltrative growth
pattern around normal glands. A
giant cell carcinoma (C, case 6;
hematoxylin–eosin, 120) compo-
nent and a large cell carcinoma
with rhabdoid variant (D, case 2;
hematoxylin–eosin staining, 120).
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without ulceration of the mucosa, then showing a kind of
inverted tumor cell growth, was suggestive of a metastasis. In
surgical samples (eight cases) and, particularly, in biopsies
(all seven cases), tumor cells showed a peculiar infiltrating
growth pattern with poorly cohesive, undifferentiated neo-
plastic cells singly and/or in small sheets dissecting the
normal-looking GI glands and invading lymphatic vessels. In
addition, in all cases, foci of preinvasive surface glandular
lesions were absent, whereas the finding of small foci of the
characteristic acinar appearance of lung adenocarcinoma in
four of eight cases was a histologic clue against a diagnosis of
primary GI adenocarcinomas rather than evidence of a met-
astatic tumor. Taken together, all the above findings strongly
supported, even on histology alone, a diagnosis of metastatic
cancer to the GI tract.
At immunohistochemistry, the tumor cells showed
TTF-1 nuclear positivity in 16 of 18 (89%) cases (Figure 2A,
B), and all cases reacted with CK7 (Figure 1C, D). The only
two TTF-1–negative cases were large cell undifferentiated
carcinomas. Overall, no immunoreactivity was recorded for
CK20 and CDX2 in tumor cells.
In six cases, the comparison between primary lung
tumors and the corresponding GI metastatic deposits dis-
played the same morphology and identical immunohisto-
chemical staining for the tested antibodies.
DISCUSSION
The actual incidence of lung cancers metastasizing to
the GI tract is uncertain, and the great majority of work on
this issue has included patients with previous history of lung
cancer; primary lung tumors presenting with GI involvement
are exceedingly uncommon,1–8 and papers on this issue
mainly consist of sporadic case reports.9–20
According to McNeill et al3 and Mosier et al,5 and as
shown in the present work, this latter occurrence seems to be
more frequent than expected and may be related to three
different factors: (1) the increased incidence of lung cancer in
women, (2) the recent increase in the number of endoscopic
examinations performed in general hospitals, and (3) the use
of immunostains by pathologists in neoplasms showing an
undifferentiated morphology. In our experience, 18 of 3432
(0.5%) new diagnoses of primary lung cancer were per-
formed on surgical or bioptic GI-tract samples.
Clinical symptoms did not predict specific information
in this setting. GI bleeding is the most common symptom-
atology in metastatic lung tumors involving the upper or
lower digestive tract, whereas obstruction with or without
perforation is frequently observed when lung cancer is in-
volved the small bowel.
Even at endoscopy, lung cancer involving the GI tract
has no peculiar features, possibly appearing as a diffuse
involvement of the intestinal mucosa, multiple nodules with
or without mucosa ulceration, or even as a single “volcano-
like” lesion mimicking a primary GI tumor.10–13
Thus, the histologic examination is the only way for
identifying metastatic tumors to the GI tract. In this regard,
although all pulmonary carcinomas may involve this ana-
tomic site, discrepancies have been reported about the most
common lung cancer histotype metastasizing to the digestive
system. Some authors5,7 have found that squamous cell car-
cinoma was the most common histologic type, whereas other,
more recent papers6,20 have observed that poorly differenti-
ated pulmonary adenocarcinomas and large cell undifferen-
tiated carcinomas seem to have a particular predilection for
the GI tract, as also emphasized by Edwards and Royle,2
FIGURE 2. Metastatic tumor cells
from lung cancer showing TTF-1
nuclear immunostaining and CK7
cytoplasmic positivity on a duode-
num biopsy (A and C, case 16; im-
munoperoxidase, 125) and small
bowel resection (B and D, case 7;
immunoperoxidase, 120).
Rossi et al. Journal of Thoracic Oncology • Volume 2, Number 2, February 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer118
Antler et al.,4 and Ginsberg et al.,22 or as experienced in
metastatic lung cancer in other sites.2
On surgical resection, the finding at low magnification
of a neoplastic growth mainly involving the serosal surface,
the perivisceral adipose tissue with or without ulceration of
the mucosa, then showing a kind of inverted tumor-cell
growth, is highly suggestive of a metastatic tumor. In addi-
tion, tumor cells often have a peculiar infiltrating growth
pattern displaying neoplastic elements that singly or in small
clusters dissect the normal GI glands without evidence of foci
of preinvasive surface glandular lesions, but with the pres-
ence of diffuse lymphovascular invasion by tumor cells. This
is especially evident on small biopsy, where lung tumor cells
may appear in a very limited number of large size and poorly
cohesive sheets of undifferentiated cells with prominent nu-
cleoli and abundant cytoplasm dispersed around normal-
looking GI glands. Even on biopsy, the absence of associated
conventional surface mucosa neoplasia or dysplasia adjacent
to the infiltrative tumor growth and the unusual morphology
for a primary GI tumor represent key features suggestive of a
metastatic neoplasm. Even in cases of GI-tract metastases
from lung adenocarcinoma, the peculiar acinar pattern of
pulmonary primary rather than GI adenocarcinomas is an
important clue to the correct diagnosis.
In addition, primary small bowel tumors form the great
majority of lymphomas and carcinoids, whereas primary
adenocarcinomas as well as other epithelial tumor entities
such as undifferentiated sarcomatoid carcinomas in this site
are very rare.8,23,24
Provided that clinical and radiological data should be
always required to confirm morphologic and immunohisto-
chemical findings, the coordinated expression of CK7 and
CK20 in tumor cells is widely used to distinguish carcinomas
of different origins.25 Lung carcinomas usually have the
CK7/CK20 immunoprofile, whereas intestinal carcino-
mas are generally believed to possess an opposite CK7/
CK20 immunophenotype.25 Although CK7 is a good
marker to detect primary lung cancer, as recently suggested
by Tomas et al.20 in a study on large cell lung carcinomas
metastasizing to the small bowel, it should be kept in mind
that primary adenocarcinomas from the rectum and small
intestine may express CK7 in a significant rate of cases and
even a loss of CK20 expression.26,27 The expression of CK7
should be employed with caution and, possibly, always tested
together with CK20 and more specific markers of lung and
intestinal tumor origin, such as the nuclear transcription
factors TTF-1 and CDX2. In the lung, TTF-1 is expressed in
a high percentage of adenocarcinomas (about 80%), in about
half of large cell and pleomorphic/sarcomatoid carcinomas,
and almost never in squamous cell carcinomas.28–32
Most important, no reactivity for TTF-1 has been re-
ported in nonpulmonary adenocarcinomas, as recently con-
firmed by Stenhouse et al.29 In our study, CK7 and TTF-1
were generally coexpressed in lung carcinomas, even when
poorly differentiated, confirming the high specificity and key
role of these markers in confirming lung primary of GI-tract
metastasis from pulmonary cancer.
CDX2 is a homeobox gene involved in intestinal dif-
ferentiation and commonly expressed in intestinal-type ade-
nocarcinomas from the GI tract but also from other sites.33
Negative staining for CDX2 as well as with the intestinal-
type CK20 in our cases further supported a metastasis from
an extraintestinal tumor.
On the clinical ground, it has also been our experience
that patients with GI-tract metastasis by lung cancer have a
very dismal prognosis, survival being limited to some weeks
to a couple of months in the great majority of cases. Anec-
dotally, a longer survival or more favorable outcome have
been demonstrated in patients undergoing palliative surgical
resection of the metastatic site.16 In three of our patients
(cases 4, 5, and 14), radiologic work-up (total-body computed
tomography and PET scans) did not show other metastases.
These patients then underwent pulmonary resection of the
primary lung tumor and cisplatinum-based chemotherapy
after surgical excision of the GI metastatic deposit. Although
the follow-up is too short (5 and 3 months, respectively) to
draw any conclusion, two patients (cases 4 and 5) are alive
and well, whereas one died from the disease after 14 months.
Although surgery for localized extracerebral and/or extraad-
renal metastasis from lung cancer still has a palliative in-
tent,34,35 similar to the present observations, some authors
have reported good clinical results in surgically resected
isolated hepatic metastasis from non-small cell lung can-
cer.36,37 Thus, one can speculate that this therapeutic option
probably merits further consideration in selected patients with
GI-tract metastatic disease from non-small cell lung cancer.
In conclusion, we reported the clinicopathologic and
immunohistochemical features of the largest series of con-
secutive lung cancers presenting at initial diagnosis with GI
involvement. The analysis of this uncommon occurrence
prompted us to consider the following take-home messages
for pathologists and clinicians: (1) Because metastatic tumors
are as common as primary carcinomas in the small bowel, the
finding of a metastatic malignancy in this site should always
be considered; (2) the finding of an undifferentiated tumor
with unusual morphology in the GI tract (and, as a basic rule,
in all organs) and the absence of dysplasia or neoplasia of the
surface mucosa may always give rise to the suspicion of a
metastatic malignancy, then leading the pathologists to em-
ploy a small panel of specific markers of pulmonary or GI
primary (TTF-1, CDX2, CK7, and CK20) in further deter-
mining the tumor site of origin; (3) GI metastasis from lung
cancer clearly represents a sign of late-stage disease associ-
ated with diffuse hematogenous tumor spread, but when
imaging studies (e.g., PET scan or MRI) show that the GI
tract represents the unique metastatic site, radical surgery of
the pulmonary primary tumors (after palliative surgery of the
GI metastasis) followed by chemotherapy should be consid-
ered as a promising and successful therapeutic option that
clearly deserves further investigation.
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